Harnessing NLRX1: a new frontier in mitigating inflammation in pulmonary hypertension.
Saved in:
| Title: | Harnessing NLRX1: a new frontier in mitigating inflammation in pulmonary hypertension. |
|---|---|
| Authors: | Xiao Y; Department of Physiology and Pathophysiology, School of Basic Medicine, Fourth Military Medical University, Changle West Road 169, Xian, 710032, People's Republic of China., Cai Z; Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Fourth Military Medical University, Xian, China., Bai M; Department of Physiology and Pathophysiology, School of Basic Medicine, Fourth Military Medical University, Changle West Road 169, Xian, 710032, People's Republic of China., Wu X; Department of Microbiology, School of Basic Medicine, Fourth Military Medical University, Changle West Road 169, Xian, 710032, People's Republic of China., Wang W; Department of Aerospace Hygiene, School of Aerospace Medicine, Fourth Military Mediacl University, Changle West Road 169, Xian, 710032, People's Republic of China. ypwl821@fmmu.edu.cn., Liu R; Department of Microbiology, School of Basic Medicine, Fourth Military Medical University, Changle West Road 169, Xian, 710032, People's Republic of China. rong4713@163.com., Luo Y; Department of Physiology and Pathophysiology, School of Basic Medicine, Fourth Military Medical University, Changle West Road 169, Xian, 710032, People's Republic of China. luoying@fmmu.edu.cn. |
| Source: | Respiratory research [Respir Res] 2025 Nov 07; Vol. 26 (1), pp. 311. Date of Electronic Publication: 2025 Nov 07. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-993X (Electronic) Linking ISSN: 14659921 NLM ISO Abbreviation: Respir Res Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2001- : London : BioMed Central Ltd. Original Publication: London : Current Science Ltd., c2000- |
| MeSH Terms: | Hypertension, Pulmonary*/metabolism , Hypertension, Pulmonary*/genetics , Hypertension, Pulmonary*/pathology , Mitochondrial Proteins*/genetics , Mitochondrial Proteins*/biosynthesis , Mitochondrial Proteins*/metabolism , Inflammation Mediators*/metabolism , Inflammation Mediators*/antagonists & inhibitors, Animals ; Mice, Inbred C57BL ; Mice, Knockout ; Mice ; Male ; Hypoxia/metabolism ; Rats ; Cells, Cultured ; Inflammation/metabolism ; Oxidative Stress/physiology ; Rats, Sprague-Dawley ; Macrophages/metabolism ; Disease Models, Animal |
| Abstract: | Competing Interests: Declarations. Ethics approval and consent to participate: The protocols in this research were sanctioned by the Institutional Animal Ethics and Use Committee of the Fourth Military Medical University. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Background: Hypoxic pulmonary hypertension (HPH) serves as a crucial link in the pathogenesis of chronic high-altitude diseases and chronic obstructive pulmonary disease (COPD), and ultimately may lead to right heart failure. Hypoxia triggers immune responses and inflammatory processes, which contribute to vascular remodeling and elevated pulmonary artery pressure. NLRX1, a member of the Nod-like receptor family, plays a significant regulatory role in immunity, antioxidation, and apoptosis. However, its role in the occurrence and development of HPH remains unknown. Methods: Wild type (WT) C57BL/6 mice and NLRX1 knockout (NLRX1 -/- ) Mice were subjected to intermittent chronic hypoxia for 6 weeks to establish a hypoxic pulmonary hypertension model that is similar to the moderate pulmonary hypertension (PH) induced by hypoxia in humans. Subsequently, data on hemodynamics and pulmonary pathomorphology were collected. Additionally, bone marrow derived macrophages (BMDMs) were cultured to determine the effects of up-regulating and down-regulating NLRX1 on cell function under hypoxia exposure. Western blotting or reverse transcription polymerase chain reaction (RT-PCR) was utilized to detect changes in inflammation factors and oxidative stress-related indicators in rat lung tissue and cultured BMDMs. Results: Hypoxia downregulates the expression of NLRX1 in the lung tissues of mice and bone marrow-derived macrophages (BMDM). Chronic hypoxia significantly increases right ventricular systolic pressure (RVSP), the ratio of right ventricle weight to left ventricle plus septum weight (RV/LV + S), and the medial width of pulmonary arterioles in NLRX1-knockout (NLRX1 -/- ) mice. NLRX1 mediates the hemodynamic response and right ventricular hypertrophy in mice with hypoxic pulmonary hypertension. The deficiency of NLRX1 upregulates inflammatory mediators by activating nuclear factor-κB (NF-κB) and simultaneously promotes oxidative stress and the activation of nuclear factor E2-related factor 2 (Nrf2). The activator NX-13 of NLRX1 can reduce the production of inflammatory cytokines in BMDMs stimulated by hypoxia and mitigate oxidative stress. Conclusions: NLRX1 may suppress hypoxia-induced lung inflammation and alleviate hypoxia-induced pulmonary hypertension through its anti-inflammatory and antioxidant properties. Therefore, targeted up-regulation of NLRX1 may offer a new strategy for the treatment of HPH. (© 2025. The Author(s).) |
| References: | Front Immunol. 2014 Apr 22;5:169. (PMID: 24795716) Hypertension. 2015 Feb;65(2):414-20. (PMID: 25421979) Theranostics. 2020 Feb 10;10(7):3138-3150. (PMID: 32194859) Circ Res. 2006 Sep 29;99(7):675-91. (PMID: 17008597) Biomolecules. 2021 Nov 30;11(12):. (PMID: 34944445) Front Physiol. 2021 May 26;12:676782. (PMID: 34122145) JACC Heart Fail. 2024 Feb;12(2):235-247. (PMID: 37140511) Circulation. 2005 Jul 26;112(4):553-62. (PMID: 16027259) Chest. 2009 Mar;135(3):794-804. (PMID: 19265089) PLoS Pathog. 2020 Sep 21;16(9):e1008854. (PMID: 32956405) J Clin Invest. 2020 Apr 1;130(4):1635-1652. (PMID: 31874109) J Hematol Oncol. 2018 Feb 26;11(1):28. (PMID: 29482578) J Virol. 2014 Apr;88(7):3705-18. (PMID: 24429360) PLoS Biol. 2019 Sep 16;17(9):e3000451. (PMID: 31525189) Methods Mol Biol. 2018;1784:29-33. (PMID: 29761385) J Biol Chem. 2010 Dec 31;285(53):41637-45. (PMID: 20959452) Nature. 2008 Jan 31;451(7178):573-7. (PMID: 18200010) Microbes Infect. 2018 Oct - Nov;20(9-10):615-625. (PMID: 29024797) Front Cell Infect Microbiol. 2020 Dec 04;10:609812. (PMID: 33344269) Nat Commun. 2023 Feb 16;14(1):871. (PMID: 36797302) Antioxidants (Basel). 2022 Feb 28;11(3):. (PMID: 35326123) Eur Respir J. 2008 Nov;32(5):1371-85. (PMID: 18978137) Phytomedicine. 2024 Apr;126:155410. (PMID: 38367422) J Clin Invest. 2015 Jun;125(6):2458-62. (PMID: 25938787) Biochim Biophys Acta Mol Cell Res. 2018 May;1865(5):721-733. (PMID: 29499228) Cytokine. 2022 Dec;160:156055. (PMID: 36194971) Front Immunol. 2019 Oct 11;10:2419. (PMID: 31681307) Nat Immunol. 2017 Dec;18(12):1299-1309. (PMID: 28967880) Am J Respir Crit Care Med. 2012 Nov 1;186(9):897-908. (PMID: 22955318) Int J Mol Sci. 2021 Jan 28;22(3):. (PMID: 33525671) Redox Biol. 2023 Nov;67:102926. (PMID: 37871533) Cell Prolif. 2021 Mar;54(3):e12986. (PMID: 33432610) Compr Physiol. 2011 Jan;1(1):295-317. (PMID: 23737174) Biochim Biophys Acta Mol Cell Res. 2024 Dec;1871(8):119852. (PMID: 39357547) Immunity. 2011 Jun 24;34(6):854-65. (PMID: 21703540) Immunity. 2011 Jun 24;34(6):843-53. (PMID: 21703539) Autophagy. 2024 Apr;20(4):809-829. (PMID: 37876250) Biosci Rep. 2019 Apr 9;39(4):. (PMID: 30837326) Cells. 2020 Oct 22;9(11):. (PMID: 33105588) J Immunol. 2019 Dec 15;203(12):3407-3415. (PMID: 31694910) J Mol Cell Biol. 2023 Apr 20;14(12):. (PMID: 36564027) |
| Grant Information: | 81770056 National Nature Science Foundation of China; 2023-YBSF-405 Key Research and Development Project of Shanxi province |
| Contributed Indexing: | Keywords: Hypoxia; Hypoxic pulmonary hypertension (HPH); Inflammation; NF-κB; NLRX1; Pulmonary vascular remodeling |
| Substance Nomenclature: | 0 (NLRX1 protein, mouse) 0 (Mitochondrial Proteins) 0 (Inflammation Mediators) |
| Entry Date(s): | Date Created: 20251107 Date Completed: 20251108 Latest Revision: 20251110 |
| Update Code: | 20251110 |
| PubMed Central ID: | PMC12595859 |
| DOI: | 10.1186/s12931-025-03364-w |
| PMID: | 41204207 |
| Database: | MEDLINE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Competing Interests: Declarations. Ethics approval and consent to participate: The protocols in this research were sanctioned by the Institutional Animal Ethics and Use Committee of the Fourth Military Medical University. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.<br />Background: Hypoxic pulmonary hypertension (HPH) serves as a crucial link in the pathogenesis of chronic high-altitude diseases and chronic obstructive pulmonary disease (COPD), and ultimately may lead to right heart failure. Hypoxia triggers immune responses and inflammatory processes, which contribute to vascular remodeling and elevated pulmonary artery pressure. NLRX1, a member of the Nod-like receptor family, plays a significant regulatory role in immunity, antioxidation, and apoptosis. However, its role in the occurrence and development of HPH remains unknown.<br />Methods: Wild type (WT) C57BL/6 mice and NLRX1 knockout (NLRX1 <sup>-/-</sup> ) Mice were subjected to intermittent chronic hypoxia for 6 weeks to establish a hypoxic pulmonary hypertension model that is similar to the moderate pulmonary hypertension (PH) induced by hypoxia in humans. Subsequently, data on hemodynamics and pulmonary pathomorphology were collected. Additionally, bone marrow derived macrophages (BMDMs) were cultured to determine the effects of up-regulating and down-regulating NLRX1 on cell function under hypoxia exposure. Western blotting or reverse transcription polymerase chain reaction (RT-PCR) was utilized to detect changes in inflammation factors and oxidative stress-related indicators in rat lung tissue and cultured BMDMs.<br />Results: Hypoxia downregulates the expression of NLRX1 in the lung tissues of mice and bone marrow-derived macrophages (BMDM). Chronic hypoxia significantly increases right ventricular systolic pressure (RVSP), the ratio of right ventricle weight to left ventricle plus septum weight (RV/LV + S), and the medial width of pulmonary arterioles in NLRX1-knockout (NLRX1 <sup>-/-</sup> ) mice. NLRX1 mediates the hemodynamic response and right ventricular hypertrophy in mice with hypoxic pulmonary hypertension. The deficiency of NLRX1 upregulates inflammatory mediators by activating nuclear factor-κB (NF-κB) and simultaneously promotes oxidative stress and the activation of nuclear factor E2-related factor 2 (Nrf2). The activator NX-13 of NLRX1 can reduce the production of inflammatory cytokines in BMDMs stimulated by hypoxia and mitigate oxidative stress.<br />Conclusions: NLRX1 may suppress hypoxia-induced lung inflammation and alleviate hypoxia-induced pulmonary hypertension through its anti-inflammatory and antioxidant properties. Therefore, targeted up-regulation of NLRX1 may offer a new strategy for the treatment of HPH.<br /> (© 2025. The Author(s).) |
|---|---|
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-025-03364-w |